?>
Contact us
Follow Us
About Us
Members
Executive Director
Why Biosimilars
The Issue
Our Solutions
Biosimilars 101
Foundations
Core Principles
FDA Regulatory Tenets
Biosimilars FAQs
Future Evolution of Biosimilar Development
Approved Biosimilars
Advocacy
Our Action
Tools
News
Resources
Get Involved
Partners
Resource type:
Biosimilars FDA Information
Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
October 3, 2019
signalgroup
FDA Patient Materials
July 3, 2019
Katie Quinn
FDA Guidance: Additional Q&A Regarding Implementation of the BPCIA (2021)
July 3, 2019
Katie Quinn
FDA Guidance: Q&A Regarding Implementation of the BPCIA (2021)
July 3, 2019
Katie Quinn
FDA Draft Guidance: Reference Product Exclusivity
July 3, 2019
Katie Quinn
FDA Draft Guidance: Clinical Pharmacology Data Use
July 3, 2019
Katie Quinn
FDA Guidance: Quality Considerations for Demonstrating Biosimilarity
July 3, 2019
Katie Quinn
FDA Guidance: Scientific Considerations in Demonstrating Biosimilarity
July 3, 2019
Katie Quinn
Biosimilars: More Treatment Choices and Innovation
July 3, 2019
Katie Quinn
FDA Biosimilar Hub
July 3, 2019
Katie Quinn
Biologics Price Competition and Innovation Act of 2009
01
02